Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients - PubMed
3 hours ago
- #Pulmonary Hypertension
- #Haemodynamics
- #Sotatercept
- Sotatercept reduces pulmonary vascular resistance (PVR) in PAH patients without significantly increasing cardiac index (CI), and may even decrease CI slightly.
- Parenteral prostacyclins, when used with or without oral therapies, significantly reduce PVR and mean pulmonary artery pressure (mPAP) while markedly increasing CI and right ventricular (RV) power.
- After sotatercept treatment, RV power decreases, whereas prostacyclins increase it, suggesting different physiological mechanisms or baseline patient characteristics.
- Baseline CI and changes in haemoglobin are independent factors associated with CI changes after sotatercept initiation, with the model explaining 44% of the variation.